This document provides a summary of GlobalData's report on the peripheral vascular stents pipeline as of December 2016. The 213-page report analyzes products currently in development, including pipeline products by stage of development, segment, territory, and regulatory path. It also reviews major companies involved in developing pipeline products and provides information on clinical trials. The report is intended to help companies formulate strategies around R&D, mergers and acquisitions, and market entry and expansion related to peripheral vascular stents.

1. Peripheral Vascular Stents - Medical DevicesPipeline Assessment,2016
Ethocle Reportshaspublished its latest MarketResearch Reporton Peripheral VascularStents - Medical
DevicesPipeline Assessment,2016. Formulatesignificantcompetitorinformation, analysis,and insights
to improveR&D strategies.Browsemarketdata tablesand figures.
PublishedOn:01-Dec-2016 | Pages: 213
Summary
GlobalData'sMedical Devicessectorreport,“Peripheral VascularStents - Medical DevicesPipeline
Assessment,2016" providesanoverview of PeripheralVascularStentscurrentlyinpipeline stage.
The report providescomprehensiveinformationonthe pipeline productswithcomparative analysisof
the productsat variousstagesof development.The reportreviewsmajorplayersinvolvedinthe pipeline
productdevelopment.Italsoprovidesinformationaboutclinical trialsinprogress,whichincludestrial
phase, trial status,trial start and enddates,and,the numberof trialsfor the keyPeripheral Vascular
Stentspipeline products.
Thisreportis preparedusingdatasourcedfromin-house databases,secondaryandprimaryresearchby
GlobalData'steamof industryexperts.
Click here to find out more about this report?
Scope
- Extensive coverage of the Peripheral VascularStentsunderdevelopment
- The report reviewsdetailsof majorpipeline productswhichincludes,productdescription,licensing
and collaborationdetailsandotherdevelopmental activities
- The report reviewsthe majorplayersinvolvedinthe developmentof Peripheral VascularStentsandlist
all theirpipeline projects
- The coverage of pipeline productsbasedonvariousstagesof developmentrangingfromEarly
DevelopmenttoApproved/Issuedstage

2. - The report provideskeyclinical trial dataof ongoingtrialsspecifictopipeline products
- Recentdevelopmentsinthe segment/industry
Get Free Sample Report
Click here for Discounts
Reasons to buy
The report enablesyouto -
- Formulate significantcompetitorinformation,analysis,andinsightstoimprove R&Dstrategies
- Identifyemergingplayerswithpotentiallystrongproductportfolioandcreate effective counter-
strategiestogaincompetitiveadvantage
- Identifyandunderstand importantanddiversetypesof Peripheral VascularStentsunderdevelopment
- Developmarket-entryandmarketexpansionstrategies
- Planmergersandacquisitionseffectivelybyidentifyingmajorplayerswiththe mostpromisingpipeline
- In-depthanalysis of the product’scurrentstage of development,territoryandestimatedlaunchdate
Table of Contents
1.1 Listof Tables6
1.2 Listof Figures12
2 Introduction13
2.1 Peripheral VascularStentsOverview13
3 ProductsunderDevelopment14
3.1 Peripheral VascularStents - PipelineProductsbyStage of Development14
3.2 Peripheral VascularStents - PipelineProductsbySegment15
3.3 Peripheral VascularStents - PipelineProductsbyTerritory16
3.4 Peripheral VascularStents - PipelineProductsbyRegulatoryPath17

3. 3.5 Peripheral VascularStents - PipelineProductsbyEstimatedApproval Date 18
3.6 Peripheral VascularStents - OngoingClinical Trials19
4 Peripheral VascularStents - Pipeline ProductsunderDevelopmentbyCompanies20
4.1 Peripheral VascularStentsCompanies - Pipeline ProductsbyStage of Development20
4.2 Peripheral VascularStents - PipelineProductsbyStage of Development22
5 Peripheral VascularStentsCompaniesandProductOverview 25
5.1 3D BiotekLLCCompanyOverview25
5.2 480 Biomedical IncCompanyOverview 26
5.3 AbbottVascularInc.CompanyOverview 30
5.4 BiotronikSE& Co KG CompanyOverview 32
5.5 BostonScientificCorpCompanyOverview 37
5.6 C. R. Bard Inc CompanyOverview43
5.7 CardiatisSA CompanyOverview45
5.8 Cook Medical Inc CompanyOverview 46
5.9 CordisCorpCompanyOverview58
5.10 CorinnovaIncCompanyOverview62
5.11 CytograftTissue EngineeringIncCompanyOverview 63
5.12 EfferentLabsInc CompanyOverview 64
5.13 ElectroformedStentsIncCompanyOverview 65
5.14 ElixirMedical CorpCompanyOverview68
5.15 HexacathCompanyOverview70
5.16 InspireMDInc CompanyOverview72
5.17 Intact Vascular,LLC CompanyOverview 74
5.18 LifetechScientific(Shenzhen)Co.,Ltd.CompanyOverview 77
5.19 LimFlowGmbHCompanyOverview 79

4. 5.20 Medinol Ltd CompanyOverview81
5.21 Medtronicplc CompanyOverview83
5.22 MicroVention,Inc.CompanyOverview 85
5.23 Natec Medical Ltd CompanyOverview 86
5.24 NexeonMedSystemsIncCompanyOverview 87
5.25 NiproCorp CompanyOverview89
5.26 NorthwesternUniversityCompanyOverview 91
5.27 NSVascular,Inc.CompanyOverview 92
5.28 PeriTecBiosciencesLtdCompanyOverview94
5.29 Stron Medical CompanyOverview96
5.30 SynergyFlowLtdCompanyOverview 98
5.31 TaewoongMedical Co.,Ltd. CompanyOverview 99
5.32 Tepha IncCompanyOverview109
5.33 TissueGenIncCompanyOverview110
5.34 Universityof MichiganCompanyOverview 112
5.35 Universityof TexasMedical Branchat GalvestonCompanyOverview 113
5.36 VascularBioresorbable TechnologiesCompanyOverview 114
5.37 VascularConceptsLtd CompanyOverview 116
5.38 Veniti IncCompanyOverview119
5.39 VeryanMedical LimitedCompanyOverview 122
5.40 VueKlarCardiovascularLtdCompanyOverview 126
5.41 Xenogenics CorporationCompanyOverview 129
6 Peripheral VascularStents- RecentDevelopments132
6.1 Nov22, 2016: MedtronicReportsSecondQuarterFinancial Results132
6.2 Nov21, 2016: VEITHsymposium2016: BIOTRONIKShowcasesPositive ResultsforPulsar-18Stentin
the SFA 134

5. 6.3 Nov18, 2016: AbbottLabs PricesPublicOfferingof 4.75% Notesdue 2036 for USD1.7 Billion135
6.4 Nov16, 2016: MedtronicReleasesFY16IntegratedPerformanceReport135
6.5 Nov15, 2016: Final PatientEnrolledforIliofemoral Venous StentStudy136
6.6 Nov15, 2016: LimFlowReceivesCEMark for PurelyPercutaneousCriticalLimbIschemiaTechnology
DesignedtoRestore Perfusionfor“NoOption”Patients136
6.7 Nov15, 2016: CEVA to workwithMedtronicfor distributionfacilityconstruction137
6.8 Nov14, 2016: AngioDynamicsPricesPublicOfferingof SharesforUSD32 Million138
6.9 Nov14, 2016: InspireMDReportsFinancial Resultsforthe ThirdQuarterEndedSeptember30, 2016
138
6.10 Nov14, 2016: NeovascReportsThirdQuarterResultsfor2016 140
6.11 Nov09, 2016: AngioDynamicsAnnouncesAdditionof New BoardMembers142
6.12 Oct 31, 2016: FDA ApprovesTOBA IIBTK Pivotal IDEClinical Study143
6.13 Oct 27, 2016: CONMED AnnouncesThirdQuarter2016 Financial Results144
6.14 Oct 26, 2016: BostonScientificAnnouncesResultsForThirdQuarter2016 145
6.15 Oct 26, 2016: Merit Medical ReportsSalesUp15.3% for the Quarter EndedSeptember30,2016
146
6.16 Oct 25, 2016: Edwards LifesciencesReportsThirdQuarterResults147
6.17 Oct 25, 2016: Bard AnnouncesThirdQuarterResults149
6.18 Oct 24, 2016: BostonScientificannouncedkeyPresentationsonEluviaDrug-ElutingVascularStent
Systemat TranscatheterCardiovascularTherapeutics2016 149
6.19 Oct 20, 2016: AkesysMedical andElixirMedical Announce FirstHumanImplantof the PRAVA
Bioresorbable ScaffoldforPeripheral VascularDisease 150
6.20 Oct 19, 2016: AbbottReportsThird-Quarter2016 Results151
6.21 Oct 18, 2016: LimFlowNamesDaniel Rose asChief ExecutiveOfficer153
6.22 Oct 11, 2016: Tepha EntersintoAgreementwithMetabolix154
6.23 Oct 10, 2016: ProfessorIanMeredithToJoinBostonScientificAsExecutiveVice PresidentAnd
Global Chief Medical Officer154
6.24 Oct 05, 2016: AngioDynamics ReportsFiscal 2017 FirstQuarter Results155

6. 6.25 Sep27, 2016: BostonScientificAcquiresEndoChoice forUSD210 MillioninTenderOffer156
6.26 Sep15, 2016: STENTYS Reports2016 First-Half Results156
6.27 Sep15, 2016: MedtronicNamesMark Ploof SeniorVice Presidentof Global Operationsand
BusinessServices157
6.28 Sep08, 2016: VENITIRaisesUSD25 MillioninSeriesDEquityFinancing158
6.29 Sep07, 2016: GORE VIABAHN EndoprosthesisMarks20 Years of ProvenPerformance 158
6.30 Sep07, 2016: InspireMDAppointsThomasKestertoBoardof Directors159
6.31 Aug 31, 2016: CookMedical NamesJean-MarcCreissel VicePresidentof OperationsinGreater
China160
6.32 Aug 25, 2016: MedtronicReportsFirstQuarterFinancial Results160
6.33 Aug 09, 2016: InspireMDReportsFinancial Resultsforthe SecondQuarterEndedJune 30,2016 163
6.34 Aug 09, 2016: NeovascReportsSecondQuarterResultsfor2016 165
6.35 Aug 03, 2016: EndoChoice AnnouncesSecondQuarter2016 Financial Results167
6.36 Aug 02, 2016: GORE TIGRIS VascularStentGainsFDA Approval forTreatmentof Peripheral Artery
Disease 169
6.37 Jul 28, 2016: BostonScientificAnnouncesResultsForSecondQuarter2016 170
6.38 Jul 27, 2016: Merit Medical ReportsSalesUp9.4% forthe QuarterEndedJune 30, 2016 171
6.39 Jul 27, 2016: CONMED AnnouncesSecondQuarter2016 Financial Results172
6.40 Jul 26, 2016: Merit Medical AnnouncesAppointmentof New Director173
6.41 Jul 26, 2016: Edwards LifesciencesReportsSecondQuarterResults173
6.42 Jul 26, 2016: Bard AnnouncesSecondQuarterResults175
6.43 Jul 25, 2016: AngioDynamicsAppointsMichael C.GreinerasNew Chief Financial Officer176
6.44 Jul 21, 2016: Svelte Medical SystemsRaisesUSD4MillioninVenture Financing176
6.45 Jul 20, 2016: AbbottReportsSecond-Quarter2016 Results176
6.46 Jul 13, 2016: BostonScientificElectsYoshiakiFujimori toBoardof Directors178
6.47 Jul 13, 2016: AngioDynamicsReportsFiscal 2016 FourthQuarterand Full Year Results179
6.48 Jul 12, 2016: STENTYS: 41% Increase inRevenuesinthe SecondQuarterof 2016 180

7. 6.49 Jul 05, 2016: NeovascReceivesNASDAQNotificationRegardingMinimumBidRequirements180
6.50 Jul 04, 2016: STENTYS: Appointmentof CardiolovascularDeviceVeteranasNew CEO181
6.51 Jun 30, 2016: NuVasiveAgreestoSettlePatentLitigationWithMedtronic181
6.52 Jun 29, 2016: InspireMDRaisesUSD14.6 MillioninPublicOfferingof PreferredStockandWarrants
182
6.53 Jun 28, 2016: GORE VIABAHN Endoprosthesis FoundtoProvideSuperiorPatencyandReduced
InterventionsVersusBalloonAngioplastyAlone forChallengingAV AccessCases182
6.54 Jun 20, 2016: VENITIAnnounces1,000thPatientTreatedWithVICIVENOUSSTENT 183
6.55 Jun 08, 2016: BostonScientificAnnouncesRestructuringProgramtoSupportLong-TermGrowth
and Innovation183
6.56 Jun 06, 2016: MedtronicOutlinesFutureGrowthVisionatInvestorDay184
6.57 May 31, 2016: MedtronicReportsFourthQuarterand Fiscal Year 2016 Financial Results184
6.58 May 13, 2016: BostonScientificAnnouncesPresentationof EluviastentsystematEuroPCR2016
187
6.59 May 10, 2016: InspireMDReportsFinancial Resultsforthe FirstQuarterEndedMarch 31, 2016 187
6.60 May 04, 2016: Positive Twelve-MonthTackOptimized BalloonAngioplastyBelow-the-Knee (TOBA-
BTK) ResultsPresentedatSCAI2016 189
6.61 May 02, 2016: A.G.SchneidermanAnnounces$306 MillionNational SettlementWithOlympus190
6.62 Apr 29, 2016: NeovascReportsFirstQuarterResultsfor2016 190
6.63 Apr 21, 2016: VENITICompletesFirstUse Of VICIVERTOVENOUSSTENT,Novel VenousStent
System193
6.64 Apr 20, 2016: AbbottReportsFirst-Quarter2016 Results193
6.65 Apr 13, 2016: STENTYS Reports38% Increase inRevenuesinFirstQuarter2016 196
6.66 Apr 07, 2016: AngioDynamicsReportsFiscal 2016 Third QuarterResults196
6.67 Apr 04, 2016: AngioDynamicsAppointsJamesC.ClemmerasNew PresidentandChief Executive
Officer197
6.68 Mar 29, 2016: NeovascAnnouncesResultsforthe FourthQuarterand Fiscal Year2015 198
6.69 Mar 16, 2016: STENTYS Reports2015 Annual Results201

8. 6.70 Mar 15, 2016: InspireMDRaisesUSD0.6 MillioninPrivate Placementof SharesandWarrants202
6.71 Mar 04, 2016: PalmazScientificAnnouncesChapter11 Filing;SeeksProspective BuyersforIts
BreakthroughTechnology202
6.72 Feb22, 2016: BostonScientificReceivesCEMark For EluviaDrug-ElutingVascularStentAnd
AnnouncesInitiationOf NewClinical Trial 203
6.73 Feb12, 2016: StentysRaisesUSD14.3 MillioninRightsOffering of Shares204
6.74 Feb08, 2016: STENTYS initiatesthe Commercializationof the firstSelf-ExpandingDrug-Elutingstent
for the Below-The-KneeIndication205
6.75 Jan 26, 2016: Positive Six-MonthTackOptimizedBalloonAngioplastyBelow-the-Knee(TOBA-BTK)
ResultsPresentedatLINC2016 205
6.76 Jan 13, 2016: STENTYS Reports81% Year-over-YearGrowthinFourth-Quarter2015 Revenues206
6.77 Jan 07, 2016: AngioDynamicsReportsFiscal2016 SecondQuarterResults207
7 Appendix209
7.1 Methodology209
7.2 AboutGlobalData212
7.3 Contact Us 212
7.4 Disclaimer212